Your Must-Attend Meeting to Advance Your Potency Assay Strategy. The inaugural Cell Therapy Potency Assay Summit is the first and only industry defining forum set to address the complexity of ...

All steps of the killing assay were conducted in an E-Plate VIEW microplate (Agilent Technologies, part number 00300601030). After background impedance was measured while 50 µL of media/well was ...

Download this application note to discover an assay solution for studying and optimizing CAR T cells that can monitor key cell attributes continuously, ... Real-Time Potency Assay for CAR T-Cell ...

The ability to quantify differentiation potential of single cells is a task of critical importance. Here we demonstrate, using over 7,000 single-cell RNA-Seq profiles, that differentiation potency ...

In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. At the 4th Cell Therapy Potency Assay Summit, we will unite analytical development ...

Designed for cell therapy potency/functional release assays; A promising new approach to help scientists characterize the tumor microenvironment, condition immune cells to fight cancer, and ...

Download this application note to discover an assay solution for studying and optimizing CAR T cells that can monitor key cell attributes continuously, capture live cell images and track the continuum ...

The 3rd Cell Therapy Potency Assay Summit will bring together 100+ analytical, QC and regulatory experts to discuss the new FDA guidance and address all pressing concerns that are limiting ...

SAN CARLOS, Calif., April 25, 2018 /PRNewswire/ -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced ...

SAN CARLOS, BioCardia®, Inc., a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of United States Patent No. 9,945,854 ...